Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

548 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial.
Ferreira JP, Collier T, Clark AL, Mamas MA, Rocca HB, Heymans S, González A, Ahmed FZ, Petutschnigg J, Mujaj B, Cuthbert J, Rouet P, Pellicori P, Mariottoni B, Cosmi F, Edelmann F, Thijs L, Staessen JA, Hazebroek M, Verdonschot J, Rossignol P, Girerd N, Cleland JG, Zannad F. Ferreira JP, et al. Among authors: collier t. Eur Heart J Cardiovasc Pharmacother. 2022 Feb 16;8(2):149-156. doi: 10.1093/ehjcvp/pvab031. Eur Heart J Cardiovasc Pharmacother. 2022. PMID: 33822033 Free article. Clinical Trial.
The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial.
Collier TJ, Pocock SJ, McMurray JJ, Zannad F, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pitt B. Collier TJ, et al. Eur Heart J. 2013 Sep;34(36):2823-9. doi: 10.1093/eurheartj/eht247. Epub 2013 Jul 17. Eur Heart J. 2013. PMID: 23864130 Clinical Trial.
Heart 'omics' in AGEing (HOMAGE): design, research objectives and characteristics of the common database.
Jacobs L, Thijs L, Jin Y, Zannad F, Mebazaa A, Rouet P, Pinet F, Bauters C, Pieske B, Tomaschitz A, Mamas M, Diez J, McDonald K, Cleland JG, Brunner-La Rocca HP, Heymans S, Latini R, Masson S, Sever P, Delles C, Pocock S, Collier T, Kuznetsova T, Staessen JA. Jacobs L, et al. Among authors: collier t. J Biomed Res. 2014 Sep;28(5):349-59. doi: 10.7555/JBR.28.20140045. Epub 2014 Jul 31. J Biomed Res. 2014. PMID: 25332706 Free PMC article.
Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial.
Girerd N, Collier T, Pocock S, Krum H, McMurray JJ, Swedberg K, Van Veldhuisen DJ, Vincent J, Pitt B, Zannad F. Girerd N, et al. Among authors: collier t. Eur Heart J. 2015 Sep 7;36(34):2310-7. doi: 10.1093/eurheartj/ehv273. Epub 2015 Jun 20. Eur Heart J. 2015. PMID: 26093641 Clinical Trial.
Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS-HF study.
Chin KL, Collier TJ, Pitt B, McMurray JJ, Swedberg K, van Veldhuisen DJ, Pocock SJ, Vincent J, Turgonyi E, Zannad F, Krum H; EMPHASIS-HF Study Investigators. Chin KL, et al. Eur J Heart Fail. 2016 Sep;18(9):1175-81. doi: 10.1002/ejhf.485. Epub 2016 Feb 2. Eur J Heart Fail. 2016. PMID: 26833642 Free article.
Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trial.
Olivier A, Pitt B, Girerd N, Lamiral Z, Machu JL, McMurray JJV, Swedberg K, van Veldhuisen DJ, Collier TJ, Pocock SJ, Rossignol P, Zannad F, Pizard A. Olivier A, et al. Eur J Heart Fail. 2017 Sep;19(9):1186-1197. doi: 10.1002/ejhf.792. Epub 2017 Mar 16. Eur J Heart Fail. 2017. PMID: 28303624 Free article. Clinical Trial.
548 results